Rationale for Conservative Management

  • Patent ductus arteriosus (PDA) is common in extremely low birth weight infants due to immature ductal smooth muscle and altered sensitivity to prostaglandins and oxygen.
  • Persistence of a ductus was historically considered pathological and thought to directly cause bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), intraventricular hemorrhage, and death.
  • Aggressive routine pharmacological (indomethacin, ibuprofen) or surgical closure was common practice.
  • Randomized trials have demonstrated that while cyclooxygenase inhibitors achieve anatomical ductal closure, they do not improve survival or long-term neurodevelopment.
  • Current neonatal practice has shifted toward expectant or conservative management, reserving medical or device closure only for hemodynamically significant PDA (hsPDA) causing severe cardiorespiratory compromise.

Landmark Clinical Trials

  • BeNeDuctus Trial (NEJM 2023):
    • Enrolled 272 infants born at <28 weeks gestation with an echocardiographically confirmed large PDA (>1.5 mm with left-to-right shunt).
    • Randomized to expectant conservative management versus early active treatment with ibuprofen.
    • The composite primary outcome (NEC, BPD, or death at 36 weeks PMA) occurred in 46.3% of the expectant group vs 63.5% of the ibuprofen group (risk difference -17.2%).
    • Expectant management was non-inferior to early ibuprofen treatment, and over 60% of infants managed expectantly achieved spontaneous ductal closure.
  • Baby-OSCAR Trial (Lancet 2023):
    • Evaluated targeted early ibuprofen within 72 hours of birth in extremely preterm infants (<29 weeks) with a large PDA on echocardiography.
    • Early targeted ibuprofen did not decrease death or moderate-to-severe BPD at 36 weeks PMA compared to placebo (56% vs 56%, RR 1.01).
  • PDA-TOLERATE Trial (J Pediatr 2019):
    • Withholding routine pharmacotherapy in moderate-to-large PDA after the first week of life did not increase BPD, death, or neurodevelopmental impairment.

Conservative (Expectant) Management Protocol

  • Fluid Optimization: Restrict total fluid intake to 120 to 130 mL/kg/day; avoid excessive fluid administration during the first week of life.
  • Ventilator Adjustments:
    • Increase PEEP to 5 to 7 cm $H_2O$ to raise pulmonary vascular resistance and decrease left-to-right transductal shunting.
    • Avoid hypocapnia ($pCO_2 < 35\text{ mmHg}$ causes pulmonary vasodilation, increasing transductal pulmonary blood flow).
  • Maintain Target Hematocrit: Keep hematocrit >35% to 40% (hemoglobin >12 to 13 g/dL) to preserve oxygen-carrying capacity and maintain blood viscosity.
  • Avoid Loop Diuretics: Furosemide stimulates renal production of prostaglandin $E_2$ and prostacyclin, maintaining ductal patency; if diuresis is necessary, use spironolactone and thiazides.

Criteria For Hemodynamically Significant PDA (hsPDA)

Treatment is reserved for infants with an echocardiographically confirmed hsPDA accompanied by clinical deterioration:

  • Internal ductal diameter >1.5 mm (or >1.4 mm/kg).
  • Left atrium to aortic root ratio ($\text{LA:Ao}$) >1.4 to 1.5.
  • Retrograde diastolic flow in the post-ductal descending aorta (diastolic steal >30% of forward flow).
  • Absent or reversed end-diastolic flow in the celiac axis, superior mesenteric artery (SMA), or middle cerebral artery (MCA).
  • Clinical features: Unweanable ventilator dependence, pulmonary hemorrhage, systemic hypotension, or oliguria unresponsive to fluid titration.

Adverse Effects Of Active Closure

Treatment ModalityAdverse EffectsClinical Consequence
IndomethacinRenal vasoconstriction, transient oliguria, increased serum creatinineGI perforation, reduced cerebral and gut blood flow velocity
IbuprofenDisplaces bilirubin from albumin binding sitesIncreased risk of free bilirubin and kernicterus; mild renal dysfunction
ParacetamolPotential hepatotoxicitySafer alternative when NSAIDs are contraindicated
Surgical LigationPost-ligation cardiac syndrome (acute LV failure, hypotension), recurrent laryngeal nerve palsyVocal cord paralysis, scoliosis, worsened long-term neurodevelopment

Pharmacotherapy For Indicated Cases

DrugDosing RegimenKey Points
Oral Ibuprofen10 mg/kg initial dose, followed by 5 mg/kg at 24 and 48 hoursOral route has superior closure rates compared to IV; lower nephrotoxicity
IV Indomethacin0.1 to 0.2 mg/kg IV every 12 to 24 hours $\times$ 3 dosesPotent COX inhibitor; causes significant mesenteric and cerebral vasoconstriction
IV Paracetamol15 mg/kg IV every 6 hours for 3 to 7 daysInhibits peroxidase subunit of PG synthetase; preferred in bleeding, low platelets, or NEC

Transcatheter Closure (Amplatzer Piccolo)

  • Transcatheter percutaneous device closure has emerged as an alternative to surgical thoracotomy.
  • The Amplatzer Piccolo Occluder is FDA-approved for closure in premature infants weighing as little as $\ge 700\text{ g}$.
  • The procedure is performed via the femoral vein in the cardiac catheterization lab under echocardiographic and fluoroscopic guidance.
  • It eliminates the risks of thoracotomy, avoids vocal cord paralysis from recurrent laryngeal nerve damage, and prevents post-ligation cardiac syndrome.